Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

New Drug Shows Promise in Clearing HIV from Brain July 25, 2024 — An experimental drug originally developed to treat cancer may help clear HIV from infected cells in the brain, according to a ...

The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...

The Bent's new season starts with a bang, thanks to their production of this gay adaptation of La Ronde by Arthur Schnitzler.

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2025, according to Statista. A large portion of that figure is from the oncology segment, which is expected ...

As healthcare costs soar, the Congressional Budget Office (CBO) has recently shed light on a hot political issue: the ...

Recommended Reading Gilead agrees to license new HIV drug in low-income countries GSK-backed ViiV Healthcare on Monday said it plans to triple the amount of its HIV prevention therapy it will make ...

Justice secretary Shabana Mahmood is facing pressure from the public to link early releases from prison to drug testing, a new poll suggests. Polling of 2,001 adults conducted by Opinion Matters ...